Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
180 hedge funds and large institutions have $836M invested in Meridian Bioscience Inc in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 67 reducing their positions, and 28 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
59% more call options, than puts
Call options by funds: $5.01M | Put options by funds: $3.15M
7% more capital invested
Capital invested by funds: $783M → $836M (+$52.8M)
0% more funds holding
Funds holding: 180 → 180 (0)
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
25% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VLKIM
Van Lanschot Kempen Investment Management
Amsterdam,
Netherlands
|
+$15.7M |
| 2 |
EIP
Epoch Investment Partners
New York
|
+$13.5M |
| 3 |
IC
Impactive Capital
New York City,
New York
|
+$6.05M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$4.92M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18M |
| 2 |
Millennium Management
New York
|
-$4.62M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$4.61M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.53M |
| 5 |
EARNEST Partners
Atlanta,
Georgia
|
-$3.44M |
VIVO Hedge Fund Activity: Q4 2021 in Review
180 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2021, worth a combined $836M — up 6.7% from $783M a quarter earlier.
Fund positioning in VIVO was balanced in Q4 2021: 28 funds opened new positions, 28 closed out, 50 added to existing stakes and 67 trimmed.
The largest buyer was Van Lanschot Kempen Investment Management, adding an estimated $15.7M. The largest seller was Deerfield Management, cutting an estimated $18M.
- 180 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $836M of Meridian Bioscience Inc stock for Q4 2021, up 6.7% quarter-over-quarter.
- 28 funds opened new Meridian Bioscience Inc positions in Q4 2021 and 28 closed out, a net change of 0 holders.
- The largest Meridian Bioscience Inc buyer in Q4 2021 was Van Lanschot Kempen Investment Management, an estimated $15.7M added.
- The largest Meridian Bioscience Inc seller in Q4 2021 was Deerfield Management, an estimated $18M sold.
Based on aggregated 13F filings for Q4 2021.